Funding agencies: This work was supported by the UTE-project/Foundation for Applied Medical Research (FIMA), by the Department of Health (63/04) and Education (17/04) of the Government of Navarra, the Mapfre Medicine Foundation, and Caja Navarra Foundation.
1531-8257/asset/MDS_left.gif?v=1&s=a99f3b698e6ae32e96dbc75c912d289e5c35649d)
1531-8257/asset/MDS_right.gif?v=1&s=4d3c8316b533aa4e41b7101a2d6fa6f082cf2505)
Brief Report
Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease†‡§
Article first published online: 9 JUN 2011
DOI: 10.1002/mds.23793
Copyright © 2011 Movement Disorder Society
Additional Information
How to Cite
Garbayo, E., Ansorena, E., Lanciego, J. L., Blanco-Prieto, M. J. and Aymerich, M. S. (2011), Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease. Mov. Disord., 26: 1943–1947. doi: 10.1002/mds.23793
- †
- ‡
Relevant conflicts of interest/financial disclosures: Nothing to report.
- §
Full financial disclosures and author roles may be found in the online version of this article.
Publication History
- Issue published online: 26 AUG 2011
- Article first published online: 9 JUN 2011
- Manuscript Accepted: 21 APR 2011
- Manuscript Revised: 19 APR 2011
- Manuscript Received: 2 NOV 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- Parkinson's disease;
- glial cell-derived neurotrophic factor;
- microspheres;
- neurodegeneration;
- 6-hydroxydopamine;
- tyrosine hydroxylase
Abstract
Background:
Glial cell-derived neurotrophic factor is a survival factor for dopaminergic neurons and a promising candidate for the treatment of Parkinson's disease. However, the delivery issue of the protein to the brain still remains unsolved. Our aim was to investigate the effect of long-term delivery of encapsulated glial cell-derived neurotrophic factor within microspheres.
Methods:
A single dose of microspheres containing 2.5 μg of glial cell-derived neurotrophic factor was implanted intrastriatally in animals 2 weeks after a 6-hydroxydopamine lesion.
Results:
The amphetamine test showed a complete behavioral recovery after 16 weeks of treatment, which was maintained until the end of the study (week 30). This effect was accompanied by an increase in dopaminergic striatal terminals and neuroprotection of dopaminergic neurons.
Conclusions:
The main achievement was the long-term neurorestoration in parkinsonian animals induced by encapsulated glial cell-derived neurotrophic factor, suggesting that microspheres may be considered as a means to deliver glial cell-derived neurotrophic factor for Parkinson's disease treatment. © 2011 Movement Disorder Society